155 related articles for article (PubMed ID: 35671121)
1. Recent advances in the treatment of advanced prostate cancer: maximizing existing therapies while searching for novel solutions.
Gourdin T
Curr Opin Oncol; 2022 May; 34(3):228-233. PubMed ID: 35671121
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in treating advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2020 May; 32(3):210-215. PubMed ID: 32209821
[TBL] [Abstract][Full Text] [Related]
3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
4. Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal.
Gourdin T
Curr Opin Oncol; 2021 May; 33(3):252-256. PubMed ID: 33818543
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Gourdin T
Curr Opin Oncol; 2018 May; 30(3):159-164. PubMed ID: 29553949
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
7. Treatments and challenges in advanced prostate cancer.
Gourdin T; Velayati A
Curr Opin Oncol; 2023 May; 35(3):200-205. PubMed ID: 36966494
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
10. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
11. Highlighting recent progress in the treatment of men with advanced prostate cancer.
Gourdin T
Curr Opin Oncol; 2024 May; 36(3):174-179. PubMed ID: 38573207
[TBL] [Abstract][Full Text] [Related]
12. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
13. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
Swami U; Hong A; El-Chaar NN; Ramaswamy K; Diessner BJ; Blauer-Peterson CJ; Sandin R; Nimke D; Agarwal N
J Urol; 2023 Jun; 209(6):1120-1131. PubMed ID: 36789668
[TBL] [Abstract][Full Text] [Related]
14. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
15. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Coenen JLLM; van den Bergh ACMF; Mehra N; Somford DM; Bergman AM; Ten Bokkel Huinink D; Fossion L; Geenen MM; Hendriks MP; van de Luijtgaarden ACM; Polee MB; Weijl NI; van de Wouw AJ; de Wit R; Uyl-de Groot CA; Gerritsen WR
Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade.
Obinata D; Hashimoto S; Uchida H; Nakahara K; Yoshizawa T; Mochida J; Yamaguchi K; Takahashi S
BMC Urol; 2023 Apr; 23(1):74. PubMed ID: 37118708
[TBL] [Abstract][Full Text] [Related]
17. Castration-Resistant Prostate Cancer: Sequencing Oral and Infusion Agents.
Starosta SB; Savage SJ
Curr Urol Rep; 2018 Jul; 19(9):73. PubMed ID: 30030649
[TBL] [Abstract][Full Text] [Related]
18. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
19. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
20. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
